This paper aims to explore the expression and clinical value of aryl hydrocarbon receptor nuclear transporter-like 1(BMAL1)and miR-552 in gastric cancer.Methods Ninety-two gastric cancer patients treated at the Affiliated Hospital of Shaoxing University of Arts and Sciences from January 2018 to January 2019 were selected and assigned to the gastric cancer group,and fourty patients with benign gastric diseases were selected and assigned to the control group.The gastric cancer tissues and adjacent tissues from the gastric cancer group,as well as the gastric lesion tissues from the control group,were collected.In addition,normal gastric mucosal epithelial cells RGM-1 and gastric cancer cells(AGS,Hs746T,MGC-803,and SGC-7901)were selected.Real-time fluorescent quantitative PCR was used to detect the expression levels of BMAL1 and miR-552 in different tissues and cells.The relationship between the expression of BMAL1 and miR-552 in gastric cancer tissues and the clinical pathological characteristics of patients was analyzed.ROC curve analysis was used to evaluate the predictive efficacy of BMAL1 and miR-552 expression in gastric cancer tissues for patient mortality.Kaplan-Meier survival curve analysis was used to investigate the relationship between BMAL1 and miR-552 expression and survival in gastric cancer patients.Multivariate logistic regression analysis was used to explore the risk factors for prognosis in gastric cancer patients.Results The expression levels of BMAL1 and miR-552 in gastric cancer tissues are significantly higher than those in adjacent tissues and gastric lesion tissues of the control group(P＜0.05),and the expression levels of BMAL1 and miR-552 in different gastric cancer cells are significantly higher than those in normal gastric mucosal epithelial cells(P＜0.05).The expression levels of BMAL1 and miR-552 in patients with poor differentiation,maximum tumor diameter≥5 cm,T3-T4,lymph node metastasis,and TNM stage Ⅲ-Ⅳ are significantly higher than those in patients with medium to well differentiation,maximum tumor diameter＜5 cm,T1-T2,no lymph node metastasis,and TNM stage Ⅰ-Ⅱ,respectively.The cut-offvalue of BMAL1 for predicting death in gastric cancer patients is 2.0,with a sensitivity of 81.2%and a specificity of 93.6%(P＜0.05).The cut-offvalue of miR-552 for predicting death in gastric cancer patients is 1.0,with a sensitivity of 97.6%and specificity of 74.2%(P＜0.05).Poor differentiation,maximum tumor diameter≥5 cm,T3-T4,lymph node metastasis,TNM stage Ⅲ-Ⅳ,BMAL1 expression≥2.0,and miR-552 expression≥1.0 are all risk factors for the prognosis of gastric cancer patients(P＜0.05).The median survival time of patients with BMAL1 expression≥2.0 and miR-552 expression≥1.0 in gastric cancer tissue is significantly shorter than that of patients with BMAL1 expression＜2.0 or miR-552 expression＜1.0(median survival time(25.3±5.2)months versus(31.4±6.6)months,Log-rank=14.677,and P＜0.05).Conclusions The expression levels of BMAL1 and miR-552 in gastric cancer tissues are significantly increased,and are correlated with histological grading,maximum tumor diameter,T staging,lymph node metastasis,TNM staging,and survival time of the patients.BMAL1 expression≥2.0 and miR-552 expression≥1.0 are both risk factors for the prognosis of gastric cancer patients,and both have the potential to serve as biomarkers for evaluating the condition and prognosis of gastric cancer patients.
Gastric cancerAryl hydrocarbon receptor nuclear translocator-like 1miR-552Clinical value
万方数据
